Dr. Blackwell’s original article, “Monthly Injectable Cabotegravir/Rilpivirine to Manage HIV Infection in Adults” has undergone the rigorous peer review process and has been accepted for publication in the Journal of the American Association of Nurse Practitioners, considered the premier journal of the NP profession. Written with collaborator Dr. Humberto Lopez-Castillo, the article examines the use of a new approach to managing HIV infection in adults using injectable antiretrovirals. The article will appear in a forthcoming issue of the journal. The abstract appears below:
The FDA recently approved a unique treatment regimen for management of HIV type-1 infection in adults. A one-time per month injection of cabotegravir/rilpivirine can replace a current, stable antiretroviral regimen in those with virological suppression, without history of treatment failure or known or suspected resistance with cabotegravir or rilpivrine. A one-month oral trial should be initiated prior to switching to the extended-release injectable formulation. Cabotegravir/rilpivirine showed continued virologic suppression without clinically relevant changes in CD4+ cell counts. Clinicians should understand this new HIV regimen, its indications and suitability for select patients, administration and dosing, interactions, and most reported adverse events.